|
|
Article: Cervarix(TM), GSK's Candidate Vaccine for Cervical Cancer, Demonstrated Sustained Efficacy for up to 4.5 Years and Broader Protection Against Cancer- Causing HPV Types.
- Article from:
- PR Newswire
- Article date:
- April 5, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Follow-up study, published in The Lancet, extends earlier findings of vaccine efficacy and protection against most prevalent cancer-causing types of the human papillomavirus (HPV)
LONDON, and RIXENSART, Belgium, April 5 /PRNewswire/ -- Cervarix(TM), GlaxoSmithKline's (GSK) candidate vaccine for cervical cancer prevention, showed 100 percent efficacy over 4.5 years against precancerous lesions associated with human papillomavirus (HPV) types 16 and 18, the two most common cancer-causing HPV types, a new follow-up study shows. HPV 16 and 18 are responsible for more than 70 percent of cervical cancers globally.
GSK's candidate vaccine for cervical cancer ...